小肝癌立体定向放射治疗的效果及预后分析

李甜甜; 孙静; 王权; 丁俊强; 王佳; 薛慧; 张弢; 段学章

doi:10.3969/j.issn.1001-5256.2018.08.022

小肝癌立体定向放射治疗的效果及预后分析

DOI: 10.3969/j.issn.1001-5256.2018.08.022

1. 北京大学三〇二临床医学院
2. 解放军第三〇二医院肿瘤放射治疗中心

基金项目:

首都特色基金(Z151100004015002)；

详细信息

中图分类号: R730.55;R735.7
计量
- 文章访问数: 2245
- HTML全文浏览量: 38
- PDF下载量: 386
- 被引次数: 4
出版历程
- 收稿日期: 2018-06-04
- 出版日期: 2018-08-20

Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors

Peking University 302 Clinical Medical School

Research funding:

摘要

摘要: 目的探讨小肝癌患者接受立体定向放射治疗的疗效、安全性以及影响预后的因素。方法回顾性分析2011年3月-2014年10月于解放军三〇二医院行立体定向放射治疗的64例小肝癌患者的临床资料。随访患者的肿瘤控制情况和治疗后不良反应。Kaplan-Meier法分析生存情况;log-rank检验和Cox比例风险模型分析影响生存的相关因素。结果共纳入64例患者72个病灶。随访460个月,中位随访时间44个月。44个病灶（61.1%）完全缓解,20个病灶（27.8%）部分缓解,5个病灶（6.9%）稳定,3个病灶（4.2%）进展。客观有效率88.9%,1、3、5年局部控制率分别为94.4%、88.1%、78.7%。1、3、5年累积生存率分别为95.3%、71.6%、55.9%;无进展生存率分别为62.3%、33.5%、10.8%。不良反应多为12级。1例患者出现了胆红素升高4级反应。另外,约1/4患者出现了3级白细胞和（或）血小板的降低,治疗后1年左右均恢复至基线水平。多因素分析显示,白蛋白-胆红素分级和肿瘤数目为影响立体定向放射治疗后小肝癌患者累积生存率的独...
- 肝肿瘤 /
- 放射疗法 /
- 预后
Abstract: Objective To investigate the clinical effect and safety of stereotactic body radiotherapy ( SBRT) in patients with small hepatocellular carcinoma and related prognostic factors. Methods A retrospective analysis was performed for the clinical data of 64 patients with small hepatocellular carcinoma who underwent SBRT in 302 Hospital of PLA from March 2011 to October 2014. The patients were followed up for tumor control and adverse events after treatment. The Kaplan-Meier method was used to calculate survival rates, log-rank test and the Cox proportional hazards model was used to analyze the influencing factors for survival. Results A total of 64 patients with 72 lesions were enrolled in this study. The patients were followed up for 4-60 months, with a median follow-up time of 44 months. Of all lesions, 44 ( 61. 1%) achieved complete response, 20 ( 27. 8%) achieved partial response, 5 ( 6. 9%) achieved a stable state, and 3 ( 4. 2%) had progression. The objective response rate was 88. 9%. The 1-, 3-, and 5-year local control rates were 94. 4%, 88. 1%, and 78. 7%, respectively, the 1-, 3-, and 5-year cumulative survival rates were 95. 3%, 71. 6% and 55. 9%, respectively, and the 1-, 3-, and5-year progression-free survival rates were 62. 3%, 33. 5%, and 10. 8%, respectively. Most of the adverse events were grade 1-2 events. One patient experienced a grade 4 elevated bilirubin. In addition, about one fourth of the patients experienced grade 3 leukopenia and/or thrombocytopenia, which increased to the baseline level at 1 year after treatment. The multivariate analysis showed that albumin-bilirubin ( ALBI) grade and number of tumors were independent risk factors for the cumulative survival rate of patients with small hepatocellular carcinoma after SBRT. Conclusion SBRT is safe and effective in the treatment of small hepatocellular carcinoma, and ALBI grade and number of tumors are associated with the survival rate of patients after treatment.
- liver neoplasms /
- radiotherapy /
- prognosis

HTML全文

参考文献(24)

[1]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.

[2]BRUIX J, REIG M, SHERMAN M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J].Gastroenterology, 2016, 150 (4) :835.

[3] ADLER JR, CHANG SD, MURPHY MJ, et al.The cyberknife:A frameless robotic system for radiosurgery[J].Stereotact Funct Neurosurg, 1997, 69 (1-4) :124-128.

[4]MENG M, WANG H, ZENG X, et al.Stereotactic body radiation therapy:A novel treatment modality for inoperable hepatocellular carcinoma[J].Drug Discov Ther, 2015, 9 (5) :372-379.

[5]JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al.Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach——the ALBI grade[J].J Clin Oncol, 2015, 33 (6) :550-558.

[6]TOYODA H, LAI PB, O'BEIRNE J, et al.Long-term impact of liver function on curative therapy for hepatocellular carcinoma:Application of the ALBI grade[J].Br J Cancer, 2016, 114 (7) :744-750.

[7]ZHANG T, SUN J, HE WP, et al.Clinical effect of Cyber Knife stereotactic radiosurgery in treatment of patients with small hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (4) :694-698. (in Chinese) 张弢, 孙静, 何卫平, 等.射波刀立体定向放射治疗小肝癌的临床效果[J].临床肝胆病杂志, 2017, 33 (4) :694-698.

[8]LI H, SUN J, ZHANG T, et al.Effect of Cyber Knife radiosurgery on survival rate of patients with recurrent liver cancer after surgery[J].J Clin Hepatol, 2017, 33 (12) :2337-2341. (in Chinese) 李欢, 孙静, 张弢, 等.射波刀治疗复发性肝癌患者的效果及预后分析[J].临床肝胆病杂志, 2017, 33 (12) :2337-2341.

[9]European Association For the Study of the Liver.EASL-EORTC Clinical Practice Guidelines:Management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (6) :908-943.

[10]BENEDICT SH, YENICE KM, DAVID F, et al.Stereotactic body radiation therapy:The report of AAPM Task Group 101[J].Med Phys, 2010, 37 (8) :4078-4101.

[11]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[C]//Seminars in Liver Disease.2010:52-60.

[12]CHEN AP, SETSER A, ANADKAT MJ, et al.Grading dermatologic adverse events of cancer treatments:The common terminology criteria for adverse events version 4.0[J].J Am Acad Dermatol, 2012, 67 (5) :1025-1039.

[13]KHOJA L, LORIGAN P, ZHOU C, et al.Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma[J].J Invest Dermatol, 2013, 133 (6) :1582-1590.

[14]VEROUX M, GROSSO G, CORONA D, et al.Age is an important predictor of kidney transplantation outcome[J].Nephrol Dial Transplant, 2012, 27 (4) :1663-1671.

[15]BLOMGREN H, LAX I, NASLUND I, et al.Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator.Clinical experience of the first thirty-one patients[J].Acta Oncol, 2009, 34 (6) :861-870.

[16]TSAI CL, HSU FM, CHENG JC.How to improve therapeutic ratio in radiotherapy of HCC[J].Liver Cancer, 2016, 5 (3) :210-220.

[17]BUJOLD A, MASSEY CA, KIM JJ, et al.Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J].J Clin Oncol, 2013, 31 (13) :1631-1639.

[18]SHAO L, SHI YX, ZHU HX, et al.Clinical study of stereotactic radiotherapy combined with Kanglaite injection in the treatment of primary liver cancer[J].Chin J Med Offic, 2017, 45 (3) :313-315. (in Chinese) 邵亮, 施艳新, 朱慧心, 等.立体定向放射治疗联合康莱特注射液治疗原发性肝癌临床研究[J].临床军医杂志, 2017, 45 (3) :313-315.

[19]SANUKI N, TAKEDA A, OKU Y, et al.Stereotactic body radiotherapy for small hepatocellular carcinoma:A retrospective outcome analysis in 185 patients[J].Acta Oncol, 2014, 53 (3) :399-404.

[20]SU T, LIANG P, LU H, et al.Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients[J].J Surg Oncol, 2016, 113 (2) :181-187.

[21]SCORSETTI M, COMITO T, COZZI L, et al.The challenge of inoperable hepatocellular carcinoma (HCC) :Results of a single-institutional experience on stereotactic body radiation therapy (SBRT) [J].J Cancer Res Clin Oncol, 2015, 141 (7) :1301-1309.

[22]KANG JK, KIM MS, CHO CK, et al.Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage therapy after incomplete transarterial chemoembolization[J].Cancer, 2012, 118 (21) :5424-5431.

[23]QI WX, FU S, ZHANG Q, et al.Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma:A systematic review and meta-analysis[J].Radiother Oncol, 2015, 114 (3) :289-295.

[24]DAHIYA D, WU TJ, LEE CF, et al.Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients:A 20-year experience[J].Surgery, 2010, 147 (5) :676-685.

施引文献